The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis

Objectives Transforming growth factor β (TGFβ) has been identified as a key player in fibrotic diseases. However, the molecular mechanisms by which TGFβ activates fibroblasts are incompletely understood. Here, the role of JunD, a member of the activator protein 1 (AP-1) family of transcription factors, as a downstream mediator of TGFβ signalling in systemic sclerosis (SSc), was investigated. Methods The expression of JunD was analysed by real-time PCR, immunofluorescence, western blotting and immunohistochemistry. The canonical Smad pathway was specifically targeted by small interfering (si)RNA. The expression of extracellular matrix proteins in JunD deficient (JunD−/−) fibroblasts was analysed by real-time PCR and hydroxyproline assays. The mouse model of bleomycin-induced dermal fibrosis was used to assess the role of JunD in experimental fibrosis. Results JunD was overexpressed in SSc skin and in cultured fibroblasts in a TGFβ dependent manner. The expression of JunD colocalised with pSmad 3 in fibrotic skin and silencing of Smad 3 or Smad 4 by siRNA prevented the induction of JunD by TGFβ. JunD−/− fibroblasts were less responsive to TGFβ and released less collagen upon stimulation with TGFβ. Moreover, JunD−/− mice were protected from bleomycin-induced fibrosis with reduced dermal thickening, decreased myofibroblast counts and lower collagen content of lesional skin. Conclusions These data demonstrate that JunD is overexpressed in SSc and that JunD is a mediator of the profibrotic effects of TGFβ. Considering that inhibitors of AP-1 signalling have recently been developed and are available for clinical trials in SSc, these findings may have translational implications.

[1]  Oliver Distler,et al.  Transcription Factor Fos-Related Antigen-2 Induces Progressive Peripheral Vasculopathy in Mice Closely Resembling Human Systemic Sclerosis , 2009, Circulation.

[2]  B. Pasche,et al.  Transforming growth factor β as a therapeutic target in systemic sclerosis , 2009, Nature Reviews Rheumatology.

[3]  R. Landewé,et al.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) , 2009, Annals of the rheumatic diseases.

[4]  S. Forbes,et al.  Hepatic fibrogenesis: from within and outwith. , 2008, Toxicology.

[5]  Y. Allanore,et al.  Systemic sclerosis: an update in 2008. , 2008, Joint, bone, spine : revue du rhumatisme.

[6]  E. Wagner,et al.  Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1 , 2008, Proceedings of the National Academy of Sciences.

[7]  Oliver Distler,et al.  Dual inhibition of c‐abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  S. Hirono,et al.  Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1 , 2008, Nature Biotechnology.

[9]  G. Gores,et al.  Cellular and molecular mechanisms of liver injury. , 2008, Gastroenterology.

[10]  S. Kaufmann,et al.  Starring stellate cells in liver immunology. , 2008, Current opinion in immunology.

[11]  O. Distler,et al.  Novel treatment approaches to fibrosis in scleroderma. , 2008, Rheumatic diseases clinics of North America.

[12]  R. Gay,et al.  Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. , 2007, Arthritis and rheumatism.

[13]  F. Verrecchia,et al.  Transforming growth factor-β and fibrosis , 2007 .

[14]  G. Reynolds,et al.  JunD is a profibrogenic transcription factor regulated by Jun N‐terminal kinase‐independent phosphorylation , 2006, Hepatology.

[15]  E. Wagner,et al.  Fos/AP‐1 proteins in bone and the immune system , 2005, Immunological reviews.

[16]  H. Drexler,et al.  Lack of JunD Promotes Pressure Overload–Induced Apoptosis, Hypertrophic Growth, and Angiogenesis in the Heart , 2005, Circulation.

[17]  D. Pisetsky,et al.  The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Weitzman,et al.  JunD protects against chronic kidney disease by regulating paracrine mitogens. , 2003, The Journal of clinical investigation.

[19]  D. Edwards,et al.  The Comparative Role of Activator Protein 1 and Smad Factors in the Regulation of Timp-1 and MMP-1 Gene Expression by Transforming Growth Factor-β1* , 2003, The Journal of Biological Chemistry.

[20]  P. Vogt Fortuitous convergences: the beginnings of JUN , 2002, Nature Reviews Cancer.

[21]  T. Medsger,et al.  Criteria for the classification of early systemic sclerosis. , 2001, The Journal of rheumatology.

[22]  E. Wagner,et al.  AP-1 in mouse development and tumorigenesis , 2001, Oncogene.

[23]  J. Weitzman,et al.  JunD protects cells from p53-dependent senescence and apoptosis. , 2000, Molecular cell.

[24]  J. Iredale,et al.  Control of the tissue inhibitor of metalloproteinases‐1 promoter in culture‐activated rat hepatic stellate cells: Regulation by activator protein‐1 DNA binding proteins , 1999, Hepatology.

[25]  J. Ortonne,et al.  Three Activator Protein-1-binding Sites Bound by the Fra-2·JunD Complex Cooperate for the Regulation of Murine Laminin α3A (lama3A) Promoter Activity by Transforming Growth Factor-β* , 1998, The Journal of Biological Chemistry.

[26]  T. Medsger Treatment of systemic sclerosis. , 1989, Rheumatic diseases clinics of North America.

[27]  J. F. Woessner,et al.  The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. , 1961, Archives of biochemistry and biophysics.

[28]  S. Gay,et al.  The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. , 2010, Arthritis and rheumatism.

[29]  J. Varga Systemic sclerosis: an update. , 2008, Bulletin of the NYU hospital for joint diseases.

[30]  Oliver Distler,et al.  Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. , 2007, Arthritis and rheumatism.

[31]  F. Verrecchia,et al.  Transforming growth factor-beta and fibrosis. , 2007, World journal of gastroenterology.

[32]  D. Edwards,et al.  The Comparative Role of Activator Protein 1 and Smad Factors in the Regulation of Timp-1 and MMP-1 Gene Expression by Transforming Growth Factor- (cid:1) 1* , 2003 .

[33]  J. Weitzman,et al.  Targeted disruption of the murine junD gene results in multiple defects in male reproductive function. , 2000, Development.

[34]  O. Eickelberg,et al.  Transforming growth factor-beta1 induces interleukin-6 expression via activating protein-1 consisting of JunD homodimers in primary human lung fibroblasts. , 1999, The Journal of biological chemistry.